Oct 22, 2014 6:50 am EDT Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
Sep 23, 2014 9:00 am EDT Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
Jan 10, 2014 7:00 am EST Atara Biotherapeutics Announces Second Closing of $52 Million Series B Financing